Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Asselbergs FW, et al. Among authors: de jong pe, de zeeuw d. Circulation. 2004 Nov 2;110(18):2809-16. doi: 10.1161/01.CIR.0000146378.65439.7A. Epub 2004 Oct 18. Circulation. 2004. PMID: 15492322 Clinical Trial.
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.
Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE; Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Hillege HL, et al. Among authors: de jong pe, de zeeuw d. Circulation. 2002 Oct 1;106(14):1777-82. doi: 10.1161/01.cir.0000031732.78052.81. Circulation. 2002. PMID: 12356629
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ; PREVEND IT Study Group. Atthobari J, et al. Among authors: de jong pe, de jong van den berg lt, de vries r. Clin Ther. 2006 Mar;28(3):432-44. doi: 10.1016/j.clinthera.2006.03.012. Clin Ther. 2006. PMID: 16750458
454 results